Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528846 | 0.89 | RAB9A (0.40) | USP30MGLLHSD11B1PDK2AOC3 | |
| SCHEMBL90838 | 0.87 | ULK1 (0.40) | ULK1HSD11B1 | |
| SCHEMBL90859 | 0.85 | USP30 (0.45) | USP30ULK1MGLLHSD11B1P2RY12 | |
| SCHEMBL91041 | 0.84 | SCN9A (0.33) | ULK1HSD11B1AOC3NPY5R | |
| SCHEMBL8546830 | 0.84 | CPT1A (0.39) | ULK1AOC3NPY5R | |
| SCHEMBL25148551 | 0.79 | USP30 (0.61) | USP30ULK1MGLLHSD11B1PYGL | |
| SCHEMBL90997 | 0.79 | NPY5R (0.35) | HSD11B1NPY5RMAPK8 | |
| SCHEMBL2884475 | 0.78 | HTR2B (0.40) | NPY5R | |
| SCHEMBL2879069 | 0.78 | HTR2B (0.40) | NPY5R | |
| SCHEMBL70995 | 0.78 | KIT (0.43) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | USP30 4154/4885ULK1 4354/4885MGLL 1415/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | USP30 4154/4885ULK1 4354/4885MGLL 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.